Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer.

Authors

null

Yusuke Arakawa

Tokushima University, Tokushima, Japan

Yusuke Arakawa , Mitsuo Shimada , Yuji Morine , Satoru Imura , Tetsuya Ikemoto , Yu Saito , Shinichiro Yamada , Masato Yoshikawa , Katsuki Miyazaki

Organizations

Tokushima University, Tokushima, Japan, Department of Surgery, Tokushima University, Tokushima, Japan

Research Funding

No funding received
None

Background: Several prognostic factors were reported in pancreatic cancer such as neutrophil lymphocyte ratio (NLR), platelet lymphocyte ration (PLR) modified GPS. Fibrinogen platelet ratio (FPR) was reported as one of the prognostic factor of resectable gastric cancer (Surgery today 2019). In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods: Between 2004 and 2019, one hundred and sixty-three patients in our institution with curative resection for pancreatic cancer were enrolled in this retrospective study. The cases of non-curative resection were excluded. The FPR was calculated with the preoperative plasma fibrinogen and the platelet counts. Cut-off value was decided with ROC curve. The patients were divided into high and low FPR group according to cut-off value. Results: The cut-off value of FPR was 25.51. In age, gender, BMI, operative factors including operative type, amount of blood loss and operative time, there was no significant difference between these two groups. Patients in low FPR group had significantly better overall survival (OS) rates and relapse-free survival (RFS) rates compared with high FPR group (p < 0.05). On multivariate analysis, the high FPR, CA19-9 > 300 U/ml and receipt of adjuvant chemotherapy were independent risk factor of post-operative recurrence. Conclusions: The FPR might be a prognostic factor of patients with resectable pancreatic cancer.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 756)

Abstract #

756

Poster Bd #

N1

Abstract Disclosures

Similar Abstracts

Abstract

2020 Gastrointestinal Cancers Symposium

Association of neutrophil, platelet, and lymphocyte ratios with prognosis in metastatic pancreatic cancer.

First Author: Jessica Allen

Abstract

2022 ASCO Gastrointestinal Cancers Symposium

Impact of nuclear factor of activated T cells (NFAT) families as a poor prognostic factor in pancreatic cancer patients.

First Author: Yuto Kamioka

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.

First Author: Kazuki Watabe